vimarsana.com
Home
Live Updates
FDA OKs First-in-Class Sotatercept for PAH : vimarsana.com
FDA OKs First-in-Class Sotatercept for PAH : vimarsana.com
FDA OKs First-in-Class Sotatercept for PAH
Sotatercept with background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone in the STELLAR trial.
Related Keywords
United States ,
Boston ,
Massachusetts ,
Aaron Waxman ,
World Heart Federation ,
American College Of Cardiology ,
World Health Organization ,
Drug Administration ,
Pulmonary Heart Diseases ,
Functional Class ,
American College ,
Thenew England Journal ,